Incyte Corporation
$ 94.65
-0.86%
24 Apr - close price
- Market Cap 18,836,722,000 USD
- Current Price $ 94.65
- High / Low $ 95.20 / 93.63
- Stock P/E 14.77
- Book Value 26.04
- EPS 6.41
- Next Earning Report 2026-04-28
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.14 %
- ROE 0.30 %
- 52 Week High 112.29
- 52 Week Low 57.77
About
Incyte Corp is an American pharmaceutical company based in Alapocas, Delaware.
Analyst Target Price
$107.36
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-10 | 2025-10-28 | 2025-07-29 | 2025-04-29 | 2025-02-10 | 2024-10-29 | 2024-07-30 | 2024-04-30 | 2024-02-13 | 2023-10-31 | 2023-08-01 | 2023-05-02 |
| Reported EPS | 1.8 | 2.26 | 1.57 | 0.8 | 1.43 | 0.54 | -1.82 | 0.64 | 1.06 | 1.1 | 0.99 | 0.37 |
| Estimated EPS | 1.91 | 1.64 | 1.47 | 0.76 | 1.55 | 0.79 | -1.55 | 0.84 | 1.16 | 1.02 | 0.83 | 0.76 |
| Surprise | -0.11 | 0.62 | 0.1 | 0.04 | -0.12 | -0.25 | -0.27 | -0.2 | -0.1 | 0.08 | 0.16 | -0.39 |
| Surprise Percentage | -5.7592% | 37.8049% | 6.8027% | 5.2632% | -7.7419% | -31.6456% | -17.4194% | -23.8095% | -8.6207% | 7.8431% | 19.2771% | -51.3158% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-04-28 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 1.2 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: INCY
2026-04-25 12:48:45
Munich Reinsurance Co Stock Corp in Munich has initiated a new position in Incyte Corporation (NASDAQ:INCY) during the fourth quarter, purchasing 61,319 shares valued at $6.07 million. This investment comes as other institutional investors have also significantly increased their holdings in Incyte, with institutional ownership reaching 96.97%. Incyte recently reported fourth-quarter EPS of $1.80, missing consensus estimates, but revenue increased by 27.8% to $1.51 billion.
2026-04-24 18:01:46
The FDA has issued an SMR letter to Incyte regarding misleading promotional claims for its cGVHD treatment, Niktimvo. Regulators argue that statements on the drug's branded website, such as those about "fast and lasting responses" and organ-level benefits, overstate the efficacy supported by clinical data. This action follows a previous SMR letter to Incyte six months Prior to this, indicating a pattern of concern regarding their promotional practices.
2026-04-24 15:23:13
Agios Pharmaceuticals is facing a critical juncture as analysts have revised EPS estimates upward despite expecting a quarterly loss for March 2026. The company's investment narrative heavily relies on the success of mitapivat for rare blood disorders, with a recent focus on seeking accelerated FDA approval for sickle cell disease. While projections show significant revenue and earnings growth by 2029, concerns about hepatocellular injury risk and the narrow drug dependence could influence investor decisions.
2026-04-23 22:07:53
Ruffer LLP significantly reduced its stake in Incyte Corporation by 42.6% in the fourth quarter, now holding 25,342 shares valued at approximately $2.51 million. Concurrently, Incyte insider Pablo J. Cagnoni sold 18,667 shares for about $1.80 million. The company's stock shows a "Hold" consensus rating from analysts, with recent earnings missing EPS estimates but exceeding revenue expectations.
2026-04-23 21:38:39
RBC Capital has initiated coverage on Dermata Therapeutics (NASDAQ: DRMA) with an outperform rating and a $40 price target, significantly above its current trading price. The firm highlighted Dermata's mCALR antibody approach for myeloproliferative neoplasms and the advancement of its lead drug candidate and other pipeline assets. RBC Capital expects the stock to appreciate as the portfolio progresses and data builds confidence in its mechanism and regulatory pathway, with InvestingPro suggesting the stock is undervalued and the company holds more cash than debt.
2026-04-23 17:29:47
Incyte Corporation maintains its "Buy" rating due to a widened undervaluation and strong non-Jakafi growth prospects. The company plans four major product launches between 2026 and 2027 to mitigate the impact of Jakafi's 2028 patent cliff, with pipeline catalysts like Jakafi XR and Opzelura EU launch. Despite its dependence on Jakafi, the stock's forward P/E suggests a significant upside, with a fair value estimate 44% above the current price.
